The critical mass of biosimilars in the US is surely getting there. My opinion: now it’s time for price competition.
Tweet Content
The critical mass of biosimilars in the US is surely getting there.
My opinion: now it’s time for price competition. Otherwise you have to ask, what was the point of it all?
Maybe I’m just a naive foreigner. But US patients deserve better.
#ACR23 @US_FDA session @RheumNow https://t.co/enHY6xffMa
Show on Archive Page
On
Display in Search Results
On
PDQ
Off